Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis.
Burhanuddin Sohail RangwalaVarisha ZuhairMuhammad Saqlain MustafaAbdullah MussaratAimen Waqar KhanFnu DanishSyeda Mahrukh Fatima ZaidiFaizan Ur RehmanMuhammad Ashir ShafiquePublished in: Future science OA (2024)
Aim: Iron deficiency (ID) is associated with heart failure (HF) in a considerable proportion of patients. To improve the quality of life, lower the frequency of hospitalizations, and lower mortality rates of chronic HF patients (HF), this meta-analysis will look into the role of iron supplementation using ferric carboxymaltose (FCM). Methods & results: From inception until 1 October 2023, we conducted a thorough literature search of electronic databases for peer-reviewed publications. Around 5229 HF patients were included, of which 2691 received FCM while 2538 received placebo. Conclusion: FCM reduces HF-related hospitalizations but doesn't improve overall or cardiovascular mortality in those with HF and ID. The overall results support FCM's role in managing iron deficiency in heart failure.
Keyphrases
- iron deficiency
- end stage renal disease
- heart failure
- systematic review
- chronic kidney disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- randomized controlled trial
- left ventricular
- machine learning
- clinical trial
- coronary artery disease
- patient reported outcomes
- risk factors
- type diabetes
- big data
- drug induced